This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Rezurock (belumosudil)
General Description:
Rezurock (belumosudil) is an oral medication used for the treatment of chronic graft-versus-host disease (cGVHD). It works by inhibiting the Rho-associated coiled-coil kinase 2 (ROCK2) pathway, which helps modulate immune responses and reduce inflammation associated with cGVHD.
Rezurock is administered orally as tablets, with dosage and treatment schedules determined by a qualified healthcare professional based on patient needs.
Getting Rezurock (belumosudil) in India:
Rezurock is currently approved in the USA. Patients in India can access it legally through a Named Patient Program (NPP) under the supervision of a licensed physician.
MitoGENE assists Indian patients in obtaining Rezurock safely, handling all regulatory approvals, import permits, and logistics to ensure a secure and compliant process.
Disease Indication:
• Chronic Graft-Versus-Host Disease (cGVHD)
Manufacturer:
Kadmon (US), a Sanofi Company
Usage:
Oral Tablets
Medicine Approved By:
• [FDA – USA]
Available Dosage Form & Package:
• 200 mg tablets, 30 tablets per pack
Shipping:
Room Temperature Shipping
Rezurock is shipped under controlled room temperature conditions (15–25°C) to maintain stability and effectiveness. Standard shipping procedures ensure the medication remains safe and uncompromised during transit.
How to Access Rezurock (belumosudil) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Rezurock (belumosudil) is not yet approved or commercially available in India, MitoGENE can assist you in accessing it legally through the Named Patient Program (NPP). Here’s how the process works:
